Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 51, Issue 1, 2011, Pages 102-106

  Richards, Duncan B ^a   Spence, Rebecca ^b   Mandagere, Arun ^b   Henderson, Linda S ^c   Magee, Mindy H ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Gilead Sciences   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Ambrisentan; digoxin; p glycoprotein

Indexed keywords

AMBRISENTAN; DIGOXIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG URINE LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT CONGESTION;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PHENYLPROPIONATES; PYRIDAZINES; YOUNG ADULT;

EID: 78650811745     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010362693     Document Type: Article

References (15)

1. Galiè N., Olschewski H., Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 ; 117: 3010-3019.
2. Gerber MJ, Dufton C., Pentikis H., Li Z., Ghofrani HA Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin, Chest. 2006 ; 130: 256S.
3. Spence R., Mandagere A., Dufton C., Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008 ; 48: 1451-1459.
4. Richards D., Walker G., Mandagere A., Magee M., Henderson L., Harris S. The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan. J Clin Pharmacol. 2009 ; 49: 719-724.
5. Assessment report for Volibris. European Medicines Evaluation Agency, 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/volibris/H-839-en6.pdf. Accessed February 19, 2010.
6. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998 ; 114: 787-792.
7. Galie N., Torbicki A., Barst B., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 ; 25: 2243-2278.
8. Aronson JK Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 1980 ; 5: 137-149.
9. Cogan JJ, Humphreys MH, Carlson CJ, Benowitz NL, Rapaport E. Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. Circulation. 1981 ; 64: 973-976.
10. Ignasiak DP, McClanahan TB, Saganek LJ, Potoczak RE, Hallak H., Gallagher KP Effects of endothelin ETA receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits. Eur J Pharmacol. 1997 ; 321: 295-300.
11. Sarich TC, Schutzer KM, Wollbratt M., Wall U., Kessler E., Eriksson UG No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol. 2004 ; 44: 935-941.
12. Borges NC, Guermani A., Mazucheli JA, Mendes GD, Moreno RA Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay. Int J Clin Pharmacol Ther. 2007 ; 45: 366-372.
13. Gibaldi M, Perrier D, eds. Pharmacokinetics. 2 nd ed. New York, NY: Marcel Dekker ; 1982.
14. Reuning RH, Sams RA, Notari RE Role of pharmacokinetics in drug dosage adjustment, I: pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs. 1973 ; 13: 127-141.
15. Mason GD, Winter ME Appropriateness of sampling times for therapeutic drug monitoring. Am J Hosp Pharm. 1984 ; 41: 1796-1801.